<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2024.1394320</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Association between serum uric acid and colorectal cancer risk in European population: a two-sample Mendelian randomization study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhou</surname>
<given-names>Jinsong</given-names>
</name>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Fu</surname>
<given-names>Rong</given-names>
</name>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Juwei</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Suhong</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/1601401"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lin</surname>
<given-names>Zhifeng</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/1365472"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lin</surname>
<given-names>Zheng</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Xin</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Xiaolu</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Yulun</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hu</surname>
<given-names>Zhijian</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref> <xref ref-type="author-notes" rid="fn004">
<sup>&#x2021;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/769201"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<institution>Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University</institution>, <addr-line>Fuzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Shilpa S. Dhar, University of Texas MD Anderson Cancer Center, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Hao Huang, Zunyi Medical University, China</p>
<p>Kathryn Hughes Barry, University of Maryland, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Zhijian Hu, <email xlink:href="mailto:huzhijian@fjmu.edu.cn">huzhijian@fjmu.edu.cn</email> </p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work and share first authorship</p>
</fn>
<fn fn-type="other" id="fn004">
<p>&#x2021;ORCID: Zhijian Hu, <uri xlink:href="https://orcid.org/0000-0002-6889-0789">orcid.org/0000-0002-6889-0789</uri>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>07</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>14</volume>
<elocation-id>1394320</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>03</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>06</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Zhou, Fu, Zhang, Zhang, Lin, Lin, Liu, Xu, Chen and Hu</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Zhou, Fu, Zhang, Zhang, Lin, Lin, Liu, Xu, Chen and Hu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Objectives</title>
<p>This study aimed to explore the potential causal associations between serum uric acid (SUA) and the risk of colorectal cancer, colon cancer and rectal cancer.</p>
</sec>
<sec>
<title>Methods</title>
<p>Twenty-six SUA-related single nucleotide polymorphisms which were identified by a large meta-analysis of genome-wide association studies (GWASs) were used as instrumental variables in the two-sample Mendelian randomization (MR) study. Meta-analyses were used to synthesize the results of multiple GWASs which were extracted from the MRC Integrative Epidemiology Unit GWAS database for each type of cancer. The inverse variance weighted (IVW) method was used as the primary MR method to analyze the association between SUA and colorectal cancer risk. Several sensitivity analyses were performed to test the robustness of results.</p>
</sec>
<sec>
<title>Results</title>
<p>The IVW method showed that there were no causal relationships between SUA and the risk of colorectal cancer [odds ratio (OR): 1.0015; 95% confidence interval (CI): 0.9975&#x2013;1.0056] and colon cancer (OR: 1.0015; 95% CI: 0.9974&#x2013;1.0055). The SUA levels were negative correlated with rectal cancer risk (OR: 0.9984; 95% CI: 0.9971&#x2013;0.9998). The similar results were observed in both males (OR: 0.9987; 95% CI: 0.9975&#x2013;0.9998) and females (OR: 0.9985; 95% CI: 0.9971&#x2013;0.9999). The sensitivity analyses suggested no evidence of heterogeneity or horizontal pleiotropy. The leave-one-out analyses showed that one SNP (rs1471633) significantly drove the causal effect of SUA on rectal cancer risk. The MR-Egger regression and weighted median both showed that there were no causal relationships between SUA and the risk of colorectal cancer and its subtypes.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Overall, there was no linear causal association between SUA and the risk of colorectal cancer. However, further research is needed to investigate the role of higher SUA levels such as hyperuricemia or gout in the occurrence of colorectal cancer.</p>
</sec>
</abstract>
<kwd-group>
<kwd>uric acid</kwd>
<kwd>colorectal cancer</kwd>
<kwd>Mendelian randomization</kwd>
<kwd>causal association</kwd>
<kwd>meta-analysis</kwd>
</kwd-group>
<counts>
<fig-count count="3"/>
<table-count count="4"/>
<equation-count count="0"/>
<ref-count count="40"/>
<page-count count="9"/>
<word-count count="3486"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Gastrointestinal Cancers: Colorectal Cancer</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Colorectal cancer is the world&#x2019;s second deadly cancer with 1.93 million new cases and 903,859 deaths in 2022. The incidence and mortality of colorectal cancer increase with age and are higher in males than females (<xref ref-type="bibr" rid="B1">1</xref>). The identification of pathogenic factors is very important for the prevention and control of colorectal cancer, but the factors driving the increasing incidence and mortality are still largely unknown. Established nonmodifiable risk factors of colorectal cancer are age, male sex and family history, and the modifiable risk factors are smoking, alcohol use, obesity and red meat (<xref ref-type="bibr" rid="B2">2</xref>). The nonmodifiable risk factors are generally immutable, so it is necessary to explore whether there are potentially modifiable risk factors for colorectal cancer.</p>
<p>Serum uric acid (SUA) is the final oxidation product of purine nucleotide degradation. Some physiological or pathological reactions will cause the imbalance of SUA metabolism, resulting in hyperuricemia (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). Hyperuricemia is a chronic progressive disease without obvious clinical symptoms and is associated with gout, cardiovascular diseases, metabolic syndrome and kidney diseases (<xref ref-type="bibr" rid="B5">5</xref>). Many studies have also explored the associations between elevated SUA levels and cancer risk, but the conclusions were inconsistent. SUA as an antioxidant with beneficial effects has been reported a protective role against cancer (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). A systematic review of prospective studies reported that elevated SUA levels had no statistically significant association with overall cancer risk and results for specific cancers were limited and mainly negative (<xref ref-type="bibr" rid="B8">8</xref>). Mounting evidence indicated that high SUA levels represent a risk factor in various cancers through generating inflammatory reactions and oxidative stress (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). For colorectal cancer, a population-based prospective cohort study found no significant association between SUA and colorectal cancer risk (<xref ref-type="bibr" rid="B11">11</xref>). A large Swedish cohort study reported that elevated SUA levels were positively associated with the risk of colorectal cancer in males (<xref ref-type="bibr" rid="B12">12</xref>). The similar results were also found in Chinese males (<xref ref-type="bibr" rid="B13">13</xref>). Another cohort study using the UK Biobank database found that SUA showed a U-shaped association with colon cancer risk in females and males with SUA &#x2264; 3.5 mg/dL and females with SUA &gt; 8.4 mg/dL had a higher risk of rectal cancer than those with SUA between 4.4 and 5.4 mg/dL (<xref ref-type="bibr" rid="B14">14</xref>). The above controversial conclusions might be attributed to potential confounding factors&#xa0;and reverse causation, which were the limitations of observational studies.</p>
<p>Mendelian randomization (MR) is a method that uses genetic variants as instrumental variables to analyze the unbiased causal effects of exposures and outcomes. Since the distribution of genetic variants is random and genotype is not influenced by diseases, it can avoid some limitations of observational studies (<xref ref-type="bibr" rid="B15">15</xref>). Kobylecki et&#xa0;al. used urate solute carrier family 2 member 9 rs7442295 genotype as an instrumental variable and found that high plasma urate levels were genetically associated with high cancer incidence and high all-cause mortality (<xref ref-type="bibr" rid="B16">16</xref>). There were potential causal associations between higher SUA levels and prostate cancer risk in East Asian population (<xref ref-type="bibr" rid="B17">17</xref>). However, the results of a one-sample MR study from the UK Biobank database did not support a causal relationship between SUA and lung cancer (<xref ref-type="bibr" rid="B18">18</xref>). Jiang et&#xa0;al. also did MR analysis to identify the causal effect of SUA on eight site-specific cancers risk and a total of six MR methods all showed no significant causality (<xref ref-type="bibr" rid="B19">19</xref>). However, it was unknown whether SUA was causally associated with colorectal cancer risk.</p>
<p>In this study, a two-sample MR study was conducted to explore the potential causal relationships between SUA and colorectal cancer risk and its subtypes with 26 single nucleotide polymorphisms (SNPs) as instrumental variables. The findings would provide additional evidences for the causal effect of SUA on the colorectal cancer risk.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<sec id="s2_1">
<title>Study design</title>
<p>The causal relationships between SUA and the risk of colorectal cancer, colon cancer and rectal cancer were inferred using two-sample MR study with SUA associated SNPs as instrumental variables. <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref> shows the diagram of two-sample MR analysis of SUA and cancer risk. Three core assumptions should be satisfied to guarantee MR effect estimates without bias. First, the SNPs should have a strong association with SUA. Second, the SNPs should have been independent of confounding. Third, the SNPs should have affected cancer risk only via SUA and could not have a direct association.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Diagram of two-sample Mendelian randomization analysis of serum uric acid levels and cancer risk. SNP: single nucleotide polymorphism; SUA: serum uric acid; GUGC: Global Urate Genetics Consortium; MR: Mendelian randomization; IEU: Integrative Epidemiology Unit; GWAS: genome-wide association study.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1394320-g001.tif"/>
</fig>
</sec>
<sec id="s2_2">
<title>Genetic instruments for SUA</title>
<p>The SNPs-SUA sample was extracted from a large meta-analysis of 48 genome-wide association studies (GWASs) of 110,347 European individuals based on Global Urate Genetics Consortium (GUGC) data. In each GWAS, genotype imputation was carried out using the HapMap 2 data as the reference (<xref ref-type="bibr" rid="B20">20</xref>). The mean (standard deviation) of SUA levels in these studies ranged from 3.9 to 6.1 mg/dL (0.92 to 1.68 mg/dL) (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S1</bold>
</xref>). To satisfy the MR assumptions, we restricted the instrumental SNPs to those highly associated with SUA levels (P&lt;5.00E-8) and used a conservative clumping threshold with r<sup>2</sup>&lt;0.001 to ensure linkage equilibrium. In addition, F-statistic value was used to assess the strength of each SNP. The SNP with F-statistic value larger than 10 was considered to have a strong potential to predict SUA levels. Finally, a total of 26 SNPs which explained 7.0% of the variance in SUA levels were screened to perform the MR analysis. The overall population and gender-specific effects for SNPs-SUA associations are displayed in <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Tables S1</bold>
</xref> and <xref ref-type="supplementary-material" rid="SM1">
<bold>S2</bold>
</xref>, respectively.</p>
</sec>
<sec id="s2_3">
<title>Genetic association with outcomes</title>
<p>The summary results of colorectal cancer and its subtypes were extracted from the latest MRC Integrative Epidemiology Unit (IEU) (University of Bristol) GWAS database (<ext-link ext-link-type="uri" xlink:href="https://gwas.mrcieu.ac.uk/">https://gwas.mrcieu.ac.uk/</ext-link>, Accessed 05 August 2023). According to the phenotypes of GWASs, they were classified as colorectal cancer, colon cancer, and rectal cancer-associated GWASs. Because there were several GWASs for each cancer, meta-analyses with random effect models were applied to synthesize the results of these GWASs.</p>
</sec>
<sec id="s2_4">
<title>Statistical analysis</title>
<p>The fixed-effect inverse variance weighted (IVW) method was used as the primary MR method to derive an overall weighted estimate of the potential causal effect of SUA levels on cancer risk. This method assumed that all SNPs were valid instruments and combined individual MR estimates across SNPs. The same analyses were conducted in overall population, males and females, respectively. In order to test the robustness of results, several sensitivity analyses were conducted. First, the significant heterogeneity indicates the presence of horizontal pleiotropy that instrumental SNPs affect the outcome not through the exposure of interest. Therefore, Cochran&#x2019;s Q test was used to assess the heterogeneity among individual SNP estimates and horizontal pleiotropy was further examined using MR-Egger regression. Second, the leave-one-out analysis was conducted to investigate the possibility that the causal association was driven by a single SNP. In addition, the MR-Egger regression and weighted median method were implemented as complements to the IVW method. The MR-Egger regression estimated the causal effects in the presence of pleiotropic effects and the weighted median method could robustly assess the causal effects even if over half of the weight came from invalid instruments.</p>
<p>All statistical analyses were performed using R software (version 4.1.2) with &#x201c;meta&#x201d; package (version 6.10) for meta-analyses, &#x201c;ggplot2&#x201d; package (version 3.4.1) for forest plots and &#x201c;TwoSampleMR&#x201d; package (version 0.5.6) for MR analyses. Two-tail P&lt;0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Association between SNP and cancer risk</title>
<p>This study included ten cancer-related GWASs containing two colorectal cancer studies (8,679 cases and 543,000 controls), four colon cancer studies (7,862 cases and 1,0657,37 controls) and four rectal cancer studies (4,803 cases and 1,457,495 controls). Details of the GWASs used in this study are shown in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>. Meta-analyses showed that none of the 26 SUA associated SNPs was significantly related to the risk of colorectal cancer, colon cancer and rectal cancer (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures S2</bold>
</xref>&#x2013;<xref ref-type="supplementary-material" rid="SM1">
<bold>S4</bold>
</xref>). The association between each SNP and cancer risk from the meta-analyses was integrated in <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>. All the 26 SNPs were used as the instrumental variables in the MR analyses for SUA-colorectal cancer and its subtypes.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Characteristics of exposure dataset and outcome datasets.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Phenotype</th>
<th valign="middle" align="left">Consortium</th>
<th valign="middle" align="left">Cases</th>
<th valign="middle" align="left">Controls</th>
<th valign="middle" align="left">Sample size</th>
<th valign="middle" align="left">Population</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">Serum uric acid</td>
<td valign="middle" align="left">GUGC</td>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left">110347</td>
<td valign="middle" align="left">European</td>
</tr>
<tr>
<td valign="middle" align="left">Colorectal cancer</td>
<td valign="middle" align="left"/>
<td valign="top" align="left">8679</td>
<td valign="top" align="left">543000</td>
<td valign="top" align="left">551679</td>
<td valign="middle" align="left">European</td>
</tr>
<tr>
<td valign="bottom" align="left">&#x2003;Ieu-b-4965</td>
<td valign="middle" align="left">UK Biobank</td>
<td valign="top" align="left">5657</td>
<td valign="top" align="left">372016</td>
<td valign="top" align="left">377673</td>
<td valign="middle" align="left">European</td>
</tr>
<tr>
<td valign="bottom" align="left">&#x2003;Finn-b-C3_COLORECTAL_EXALLC</td>
<td valign="middle" align="left">FinnGen</td>
<td valign="top" align="left">3022</td>
<td valign="top" align="left">170984</td>
<td valign="top" align="left">174006</td>
<td valign="middle" align="left">European</td>
</tr>
<tr>
<td valign="middle" align="left">Colon cancer</td>
<td valign="middle" align="left"/>
<td valign="top" align="left">7862</td>
<td valign="top" align="left">1065737</td>
<td valign="top" align="left">1073599</td>
<td valign="middle" align="left">European</td>
</tr>
<tr>
<td valign="top" align="left">Ukb-d-C3_COLON</td>
<td valign="bottom" align="left">Neale lab</td>
<td valign="top" align="left">2437</td>
<td valign="top" align="left">358757</td>
<td valign="top" align="left">361194</td>
<td valign="middle" align="left">European</td>
</tr>
<tr>
<td valign="top" align="left">Ukb-d-C18</td>
<td valign="bottom" align="left">Neale lab</td>
<td valign="top" align="left">2226</td>
<td valign="top" align="left">358968</td>
<td valign="top" align="left">361194</td>
<td valign="middle" align="left">European</td>
</tr>
<tr>
<td valign="top" align="left">Finn-b-C3_COLON_EXALLC</td>
<td valign="bottom" align="left">FinnGen</td>
<td valign="top" align="left">1803</td>
<td valign="top" align="left">174006</td>
<td valign="top" align="left">175809</td>
<td valign="middle" align="left">European</td>
</tr>
<tr>
<td valign="top" align="left">Finn-b-C3_COLON_ADENO_EXALLC</td>
<td valign="middle" align="left">FinnGen</td>
<td valign="top" align="left">1396</td>
<td valign="top" align="left">174006</td>
<td valign="top" align="left">175402</td>
<td valign="middle" align="left">European</td>
</tr>
<tr>
<td valign="middle" align="left">Rectal cancer</td>
<td valign="middle" align="left"/>
<td valign="top" align="left">4803</td>
<td valign="top" align="left">1457495</td>
<td valign="top" align="left">1461128</td>
<td valign="middle" align="left">European</td>
</tr>
<tr>
<td valign="bottom" align="left">Ukb-b-19425</td>
<td valign="bottom" align="left">MRC-IEU</td>
<td valign="bottom" align="left">1085</td>
<td valign="bottom" align="left">461925</td>
<td valign="bottom" align="left">463010</td>
<td valign="middle" align="left">European</td>
</tr>
<tr>
<td valign="bottom" align="left">Ukb-b-1251</td>
<td valign="bottom" align="left">MRC-IEU</td>
<td valign="bottom" align="left">1470</td>
<td valign="bottom" align="left">461540</td>
<td valign="bottom" align="left">463010</td>
<td valign="middle" align="left">European</td>
</tr>
<tr>
<td valign="bottom" align="left">Ukb-d-C_RECTUM</td>
<td valign="middle" align="left">Neale lab</td>
<td valign="bottom" align="left">1170</td>
<td valign="bottom" align="left">360024</td>
<td valign="bottom" align="left">360024</td>
<td valign="middle" align="left">European</td>
</tr>
<tr>
<td valign="bottom" align="left">Finn-b-C3_RECTUM_EXALLC</td>
<td valign="middle" align="left">FinnGen</td>
<td valign="bottom" align="left">1078</td>
<td valign="bottom" align="left">174,006</td>
<td valign="bottom" align="left">175084</td>
<td valign="middle" align="left">European</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>GUGC, Global Urate Genetics Consortium; MRC-IEU, MRC Integrative Epidemiology Unit.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Forest plots of the associations between SNPs and the risk of colorectal cancer, colon cancer, and rectal cancer. SNP: single nucleotide polymorphism.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1394320-g002.tif"/>
</fig>
</sec>
<sec id="s3_2">
<title>Association between SUA and cancer risk</title>
<p>There was no association between SUA and colorectal cancer risk [odds ratio (OR): 1.0015; 95% confidence interval (CI): 0.9975, 1.0056]. The similar result was also found in males (OR:0.9989; 95%CI: 0.9968, 1.0009) and females (OR:0.9992; 95%CI: 0.9976, 1.0009). Similarly, the SUA levels were not significantly associated with colon cancer in overall population [(OR (95% CI): 1.0015 (0.9974, 1.0055)], males [(OR (95% CI): 1.0013 (0.9978, 1.0048)] and females [(OR (95% CI): 1.0016 (0.9973, 1.0059)]. However, the IVW method indicated that there was causal relationship between SUA and rectal cancer risk. The elevated SUA levels could significantly reduce the risk of rectal cancer (OR: 0.9984; 95% CI: 0.9971, 0.9998). The similar result was also found in males (OR: 0.9987; 95% CI: 0.9975, 0.9998) and females (OR: 0.9985; 95% CI: 0.9971, 0.9999) (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>).</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Mendelian randomization estimates of the causal relationships between serum uric acid levels and cancer risk using inverse variance weighted method.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" align="left">Population</th>
<th valign="middle" rowspan="2" align="left">nsnp</th>
<th valign="middle" colspan="2" align="left">Colorectal cancer</th>
<th valign="middle" colspan="2" align="left">Colon cancer</th>
<th valign="bottom" colspan="2" align="left">Rectal Cancer</th>
</tr>
<tr>
<th valign="middle" align="left">OR (95% CI)</th>
<th valign="middle" align="left">P</th>
<th valign="middle" align="left">OR (95% CI)</th>
<th valign="middle" align="left">P</th>
<th valign="middle" align="left">OR (95% CI)</th>
<th valign="middle" align="left">P</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">Overall</td>
<td valign="middle" align="left">26</td>
<td valign="middle" align="left">1.0015 (0.9975, 1.0056)</td>
<td valign="middle" align="left">0.459</td>
<td valign="middle" align="left">1.0015 (0.9974, 1.0055)</td>
<td valign="middle" align="left">0.459</td>
<td valign="middle" align="left">0.9984 (0.9971, 0.9998)</td>
<td valign="middle" align="left">0.028</td>
</tr>
<tr>
<td valign="middle" align="left">Male</td>
<td valign="middle" align="left">26</td>
<td valign="middle" align="left">0.9989 (0.9968, 1.0009)</td>
<td valign="middle" align="left">0.285</td>
<td valign="middle" align="left">1.0013 (0.9978, 1.0048)</td>
<td valign="middle" align="left">0.459</td>
<td valign="middle" align="left">0.9987 (0.9975, 0.9998)</td>
<td valign="middle" align="left">0.025</td>
</tr>
<tr>
<td valign="middle" align="left">Female</td>
<td valign="middle" align="left">26</td>
<td valign="middle" align="left">0.9992 (0.9976, 1.0009)</td>
<td valign="middle" align="left">0.364</td>
<td valign="middle" align="left">1.0016 (0.9973, 1.0059)</td>
<td valign="middle" align="left">0.467</td>
<td valign="middle" align="left">0.9985 (0.9971, 0.9999)</td>
<td valign="middle" align="left">0.037</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>OR, odds ratio; CI, confidence interval.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_3">
<title>Sensitivity analysis</title>
<p>The Cochran&#x2019;s Q tests showed that there was no heterogeneity across SNPs. The P values of the MR-Egger regressions were all greater than 0.05, suggesting that there was no horizontal pleiotropy (<xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>). The leave-one-out analyses found that rs1471633 in the PDZK1 gene had great possibility to drive the causal association between SUA and rectal cancer risk in overall population, males and females (<xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3A&#x2013;H</bold>
</xref>). The causal association became not statistically significant if rs1471633 was excluded in the MR analysis (<xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3C, F, I</bold>
</xref>). The MR-Egger regression and weighted median method both showed that there were no causal relationships between SUA and the risk of colorectal cancer, colon cancer and rectal cancer (<xref ref-type="table" rid="T4">
<bold>Table&#xa0;4</bold>
</xref>).</p>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Heterogeneity and MR-Egger pleiotropy test for the causal relationships between serum uric acid levels and cancer risk.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" rowspan="2" align="left">Phenotype</th>
<th valign="top" align="left">Cochran&#x2019;s Q test</th>
<th valign="top" rowspan="2" align="left">P</th>
<th valign="top" align="left">MR-Egger</th>
<th valign="top" rowspan="2" align="left">SE</th>
<th valign="top" rowspan="2" align="left">P</th>
</tr>
<tr>
<th valign="top" align="left">Q</th>
<th valign="top" align="left">Intercept</th>
</tr>
</thead>
<tbody>
<tr>
<th valign="top" colspan="6" align="left">Overall</th>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Colorectal <break/>&#x2003;cancer</td>
<td valign="top" align="left">12.64</td>
<td valign="top" align="left">0.981</td>
<td valign="top" align="left">-1.09E04</td>
<td valign="top" align="left">1.82E-04</td>
<td valign="top" align="left">0.554</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Colon cancer</td>
<td valign="top" align="left">7.31</td>
<td valign="top" align="left">0.999</td>
<td valign="top" align="left">-1.68E04</td>
<td valign="top" align="left">5.39E-04</td>
<td valign="top" align="left">0.758</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Rectal cancer</td>
<td valign="top" align="left">9.15</td>
<td valign="top" align="left">0.998</td>
<td valign="top" align="left">1.55E-04</td>
<td valign="top" align="left">1.88E-04</td>
<td valign="top" align="left">0.420</td>
</tr>
<tr>
<th valign="top" colspan="6" align="left">Male</th>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Colorectal <break/>&#x2003;cancer</td>
<td valign="top" align="left">12.46</td>
<td valign="top" align="left">0.982</td>
<td valign="top" align="left">-9.24E05</td>
<td valign="top" align="left">2.04E04</td>
<td valign="top" align="left">0.655</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Colon cancer</td>
<td valign="top" align="left">7.31</td>
<td valign="top" align="left">0.999</td>
<td valign="top" align="left">-1.56E04</td>
<td valign="top" align="left">5.22E04</td>
<td valign="top" align="left">0.767</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Rectal cancer</td>
<td valign="top" align="left">8.96</td>
<td valign="top" align="left">0.998</td>
<td valign="top" align="left">1.51E04</td>
<td valign="top" align="left">1.72E04</td>
<td valign="top" align="left">0.389</td>
</tr>
<tr>
<th valign="top" colspan="6" align="left">Female</th>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Colorectal <break/>&#x2003;cancer</td>
<td valign="top" align="left">12.78</td>
<td valign="top" align="left">0.979</td>
<td valign="top" align="left">-1.17E04</td>
<td valign="top" align="left">1.70E04</td>
<td valign="top" align="left">0.496</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Colon cancer</td>
<td valign="top" align="left">7.33</td>
<td valign="top" align="left">0.999</td>
<td valign="top" align="left">-1.58E04</td>
<td valign="top" align="left">5.76E04</td>
<td valign="top" align="left">0.786</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Rectal cancer</td>
<td valign="top" align="left">9.60</td>
<td valign="top" align="left">0.998</td>
<td valign="top" align="left">7.62E05</td>
<td valign="top" align="left">1.99E04</td>
<td valign="top" align="left">0.705</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>SE, standard error.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Leave-one-out analyses for serum uric acid levels on cancer.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1394320-g003.tif"/>
</fig>
<table-wrap id="T4" position="float">
<label>Table&#xa0;4</label>
<caption>
<p>Mendelian randomization estimates of the causal relationships between serum uric acid levels and cancer risk using MR-Egger and Weighted median method.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" align="left">Population</th>
<th valign="middle" rowspan="2" align="left">nsnp</th>
<th valign="middle" colspan="2" align="left">Colorectal cancer</th>
<th valign="middle" colspan="2" align="left">Colon cancer</th>
<th valign="middle" colspan="2" align="left">Rectal cancer</th>
</tr>
<tr>
<th valign="middle" align="left">OR (95% CI)</th>
<th valign="middle" align="left">P</th>
<th valign="middle" align="left">OR (95% CI)</th>
<th valign="middle" align="left">P</th>
<th valign="middle" align="left">OR (95% CI)</th>
<th valign="middle" align="left">P</th>
</tr>
</thead>
<tbody>
<tr>
<th valign="middle" colspan="8" align="left">MR-Egger</th>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Overall</td>
<td valign="middle" align="left">26</td>
<td valign="middle" align="left">1.0046 (0.9851, 1.0245)</td>
<td valign="middle" align="left">0.652</td>
<td valign="middle" align="left">1.0046 (0.9851, 1.0246)</td>
<td valign="middle" align="left">0.652</td>
<td valign="middle" align="left">0.9959 (0.9896, 1.0022)</td>
<td valign="middle" align="left">0.216</td>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Male</td>
<td valign="middle" align="left">26</td>
<td valign="middle" align="left">0.9994 (0.9963, 1.0025)</td>
<td valign="middle" align="left">0.721</td>
<td valign="middle" align="left">1.0038 (0.9874, 1.0205)</td>
<td valign="middle" align="left">0.657</td>
<td valign="middle" align="left">0.9965 (0.9915, 1.0015)</td>
<td valign="middle" align="left">0.181</td>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Female</td>
<td valign="middle" align="left">26</td>
<td valign="middle" align="left">0.9997 (0.9976, 1.0018)</td>
<td valign="middle" align="left">0.773</td>
<td valign="middle" align="left">1.0047 (0.9824, 1.0274)</td>
<td valign="middle" align="left">0.687</td>
<td valign="middle" align="left">0.9972 (0.9903, 1.0041)</td>
<td valign="middle" align="left">0.433</td>
</tr>
<tr>
<th valign="middle" colspan="8" align="left">Weighted median</th>
</tr>
<tr>
<td valign="middle" align="left">Overall</td>
<td valign="middle" align="left">26</td>
<td valign="middle" align="left">1.0022 (0.9979, 1.0065)</td>
<td valign="middle" align="left">0.316</td>
<td valign="middle" align="left">1.0022 (0.9979, 1.0065)</td>
<td valign="middle" align="left">0.316</td>
<td valign="middle" align="left">0.9992 (0.9973, 1.0010)</td>
<td valign="middle" align="left">0.357</td>
</tr>
<tr>
<td valign="middle" align="left">Male</td>
<td valign="middle" align="left">26</td>
<td valign="middle" align="left">0.9990 (0.9967, 1.0014)</td>
<td valign="middle" align="left">0.433</td>
<td valign="middle" align="left">1.0020 (0.9982, 1.0057)</td>
<td valign="middle" align="left">0.301</td>
<td valign="middle" align="left">0.9993 (0.9977, 1.0008)</td>
<td valign="middle" align="left">0.340</td>
</tr>
<tr>
<td valign="middle" align="left">Female</td>
<td valign="middle" align="left">26</td>
<td valign="middle" align="left">0.9937 (0.9977, 1.0011)</td>
<td valign="middle" align="left">0.467</td>
<td valign="middle" align="left">1.0023 (0.9976, 1.0070)</td>
<td valign="middle" align="left">0.339</td>
<td valign="middle" align="left">0.9992 (0.9974, 1.0012)</td>
<td valign="middle" align="left">0.402</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>OR, odds ratio; CI, confidence interval.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>The uric acid is a very important metabolite in human body. It is the end product of the oxidation of xanthine and hypoxanthine catalyzed by xanthine oxidoreductase. This study conducted a two-sample MR study to explore the potential causal relationship between SUA and colorectal cancer risk with GWAS databases available online. The SUA was found causal effect on the risk of rectal cancer with IVW method, but the sensitivity analyses did not support the finding. The similar result was also observed in males and females, respectively.</p>
<p>More and more studies supported the carcinogenic effect of SUA. It was reported that the activation of xanthine oxidase during SUA production leads to the increase of reactive oxygen species (ROS) <italic>in vivo</italic> (<xref ref-type="bibr" rid="B21">21</xref>). ROS activated signaling pathways related to proliferation, survival, angiogenesis and metastasis, promote the occurrence, development and metastasis of tumors (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>). SUA could also cause the upregulation of mRNA levels of inflammasome&#x2010;related genes (e.g. IL&#x2010;1&#x3b2; and NLRP3) through monosodium urate crystals and soluble uric acid, giving rise to oncogenes potential (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). Yiu et&#xa0;al. conducted a cohort study on 493,281 persons and found that altered SUA levels were associated with the risk of hepatobiliary, kidney, nonmelanoma skin and other cancers in males, head and neck and other cancers in females (<xref ref-type="bibr" rid="B12">12</xref>). An UK cohort study including 444,462 participants showed that high SUA levels were associated with an increased risk of pancreatic cancer and kidney cancer in females and gallbladder cancer in males (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). SUA was also found positively associated with the risk of prostate, esophagus, stomach, liver, pancreatic, lung, ovarian, renal and bladder cancers in two prospective studies in Korean population (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>). A meta-analysis found that gout was a risk factor of urological cancers, digestive system cancers and lung cancer (<xref ref-type="bibr" rid="B30">30</xref>). Of the above reported cancers that were positively associated with SUA, only non-tobacco related cancer and prostate cancer were found causal relationships with SUA in published MR studies (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). Similarly, several cohort studies reported that high SUA levels increased the risk of colorectal cancer in Swedish (<xref ref-type="bibr" rid="B12">12</xref>) and cancer in Chinese males (<xref ref-type="bibr" rid="B13">13</xref>). However, this MR study did not find positive causal associations between SUA and the risk of colorectal cancer, colon cancer and rectal cancer. It implied that the results of previous cohort studies may be affected by unobservable confounding factors.</p>
<p>Ames et&#xa0;al. firstly proposed that SUA as an antioxidant and scavenger of free radicals was working on singlet oxygen which can reduce the risk of various cancer types (<xref ref-type="bibr" rid="B31">31</xref>). The urate could activate potent immune stimulants and trigger anticancer immune response by reversing immunosuppression or as an adjuvant (<xref ref-type="bibr" rid="B32">32</xref>). In this MR study, it was found that SUA was a protective agent against rectal cancer and the protective effect of SUA on rectal cancer risk was influenced by rs1471633. The rs1471633 was reported to correlate with the decreasing trend of PDZK1 mRNA, whose protein had been shown to be a key regulatory scaffolding protein in tethering urate transportsome complex (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>). The previous studies reported inconsistent expression levels of PDZK1 across different cancers. The low-level PDZK1 expression had been reported in renal cell carcinoma (<xref ref-type="bibr" rid="B35">35</xref>) and gastric cancer (<xref ref-type="bibr" rid="B36">36</xref>), and exhibited tumor suppressive effects. In contrast, the PDZK1 expression was upregulated in breast cancer (<xref ref-type="bibr" rid="B37">37</xref>), thyroid cancer (<xref ref-type="bibr" rid="B38">38</xref>) and hepatocellular carcinoma (<xref ref-type="bibr" rid="B39">39</xref>). Therefore, further research is needed to explore the effect of PDZK1 expression on rectal cancer risk. However, the causal association between SUA and rectal cancer risk was not found in the MR-Egger regression and weighted median method. Given the robustness of results, the SUA levels were considered no causal relationship with rectal cancer risk.</p>
<p>Mi et&#xa0;al. reported that lowest uric acid groups (&#x2264;3.5 mg/dL) and highest uric acid groups (&gt;8.4 mg/dL) both had higher risk of colorectal cancer compared with the reference groups (4.4~5.4 mg/dl), and concluded the U-shaped association between SUA and colorectal cancer risk (<xref ref-type="bibr" rid="B14">14</xref>). It was demonstrated that SUA was a powerful antioxidant at physiological concentrations, while it was a pro-oxidant molecule at high intracellular concentrations (<xref ref-type="bibr" rid="B40">40</xref>). The SUA levels as continuous variable in this MR study were relatively in the normal range which may limit the correlation analyses between SUA and colorectal cancer risk. Besides, the results of correlation analyses may vary when SUA had different types of variables in the models. Therefore, further research is needed to investigate the role of higher SUA levels such as hyperuricemia or gout in the occurrence of colorectal cancer.</p>
<p>This study had some strengths. First, MR analysis was used to analyze the causal effects of SUA on colorectal cancer risk to avoid confounding and reverse causality biases. The sensitivity analyses were applied to increase the robustness of the obtained results. Second, the data of colon cancer and rectal cancer from more variety of databases were abstracted to assess the causal effects of SUA on colorectal cancer risk. Moreover, meta-analyses with random effect models incorporated all available GWASs summary data to analyze the genetic association with colorectal cancer.</p>
<p>Several issues should be considered in this study. First, the causal effect obtained in MR study did not indicate an effect on the risk of colorectal cancer after changing SUA levels. Second, the causality between SUA and colorectal cancer risk may also vary by within or out of the normal range for SUA levels. The SUA levels may not be a simple linear association but a U-shaped or J-shaped association with cancer risk. This study was limited to the absence of information about SNPs-SUA and SNPs-cancer stratified by SUA levels in the available GWAS datasets. Third, the results may only be extrapolated to the European population. Future studies could consider other ethnicities and appropriate stratification analyses.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<title>Conclusions</title>
<p>Overall, there was no linear causal association between SUA and the risk of colorectal cancer. However, further research is needed to investigate the role of higher SUA levels such as hyperuricemia or gout in the occurrence of colorectal cancer.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>Publicly available datasets were analyzed in this study. This data can be found here: The GWASs used in this study can be available from the latest MRC Integrative Epidemiology Unit GWAS database at <uri xlink:href="https://gwas.mrcieu.ac.uk">https://gwas.mrcieu.ac.uk</uri>.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>JSZ: Formal Analysis, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. RF: Conceptualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. JWZ: Validation, Writing &#x2013; original draft. SHZ: Validation, Writing &#x2013; original draft. ZFL: Validation, Writing &#x2013; original draft. ZL: Project administration, Writing &#x2013; review &amp; editing. XL: Data curation, Writing &#x2013; original draft. XLX: Data curation, Writing &#x2013; original draft. YLC: Data curation, Writing &#x2013; original draft. ZJH: Conceptualization, Supervision, Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Joint Fund project for Science and Technology Innovation of Fujian Province (Grant number: 2020Y9018) and Natural Science Foundation of Fujian Province (Grant number: 2023J01317). The funding sources have no role in study design, data collection, analysis, interpretation and the writing of the manuscript.</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2024.1394320/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2024.1394320/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet_1.pdf" id="SM1" mimetype="application/pdf"/>
</sec>
<fn-group>
<title>Abbreviations</title>
<fn fn-type="abbr">
<p>SUA, serum uric acid; MR, Mendelian randomization; SNP, single nucleotide polymorphism; GWAS, genome-wide association study; GUGC, Global Urate Genetics Consortium; IEU, Integrative Epidemiology Unit; IVW, inverse variance weighted; OR, odds ratio; CI, confidence interval; ROS, reactive oxygen species.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bray</surname> <given-names>F</given-names>
</name>
<name>
<surname>Laversanne</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sung</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ferlay</surname> <given-names>J</given-names>
</name>
<name>
<surname>Siegel</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Soerjomataram</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source>. (<year>2024</year>) <volume>74</volume>:<page-range>229&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3322/caac.21834</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sninsky</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Shore</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Lupu</surname> <given-names>GV</given-names>
</name>
<name>
<surname>Crockett</surname> <given-names>SD</given-names>
</name>
</person-group>. <article-title>Risk factors for colorectal polyps and cancer</article-title>. <source>Gastrointest Endosc Clin N Am</source>. (<year>2022</year>) <volume>32</volume>:<fpage>195</fpage>&#x2013;<lpage>213</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.giec.2021.12.008</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Update on the epidemiology, genetics, and therapeutic options of hyperuricemia</article-title>. <source>Am J Transl Res</source>. (<year>2020</year>) <volume>12</volume>:<page-range>3167&#x2013;81</page-range>.</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Huangfu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>R</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Hyperuricemia and cardiovascular disease</article-title>. <source>Curr Pharm Des</source>. (<year>2019</year>) <volume>25</volume>:<page-range>700&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/1381612825666190408122557</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gill</surname> <given-names>D</given-names>
</name>
<name>
<surname>Cameron</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Burgess</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Doherty</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Karhunen</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Urate, blood pressure, and cardiovascular disease: evidence from mendelian randomization and meta-analysis of clinical trials</article-title>. <source>Hypertension</source>. (<year>2021</year>) <volume>77</volume>:<page-range>383&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.16547</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuo</surname> <given-names>C-F</given-names>
</name>
<name>
<surname>See</surname> <given-names>L-C</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>K-H</given-names>
</name>
<name>
<surname>Chou</surname> <given-names>I-J</given-names>
</name>
<name>
<surname>Chiou</surname> <given-names>M-J</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>S-F</given-names>
</name>
</person-group>. <article-title>Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality</article-title>. <source>Rheumatol (Oxford)</source>. (<year>2013</year>) <volume>52</volume>:<page-range>127&#x2013;34</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/rheumatology/kes223</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taghizadeh</surname> <given-names>N</given-names>
</name>
<name>
<surname>Vonk</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Boezen</surname> <given-names>HM</given-names>
</name>
</person-group>. <article-title>Serum uric acid levels and cancer mortality risk among males in a large general population-based cohort study</article-title>. <source>Cancer Causes Control</source>. (<year>2014</year>) <volume>25</volume>:<page-range>1075&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10552&#x2013;014-0408&#x2013;0</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Serum uric acid increases risk of cancer incidence and mortality: A systematic review and meta-analysis</article-title>. <source>Mediators Inflammation</source>. (<year>2015</year>) <volume>2015</volume>:<elocation-id>764250</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2015/764250</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strasak</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Rapp</surname> <given-names>K</given-names>
</name>
<name>
<surname>Hilbe</surname> <given-names>W</given-names>
</name>
<name>
<surname>Oberaigner</surname> <given-names>W</given-names>
</name>
<name>
<surname>Ruttmann</surname> <given-names>E</given-names>
</name>
<name>
<surname>Concin</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28 000 older Austrian women</article-title>. <source>Ann Oncol</source>. (<year>2007</year>) <volume>18</volume>:<page-range>1893&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/annonc/mdm338</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>L</given-names>
</name>
<name>
<surname>Sui</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Friend or foe? An unrecognized role of uric acid in cancer development and the potential anticancer effects of uric acid-lowering drugs</article-title>. <source>J Cancer</source>. (<year>2020</year>) <volume>11</volume>:<page-range>5236&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7150/jca.46200</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>K&#xfc;hn</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sookthai</surname> <given-names>D</given-names>
</name>
<name>
<surname>Graf</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Sch&#xfc;bel</surname> <given-names>R</given-names>
</name>
<name>
<surname>Freisling</surname> <given-names>H</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Albumin, bilirubin, uric acid and cancer risk: results from a prospective population-based study</article-title>. <source>Br J Cancer</source>. (<year>2017</year>) <volume>117</volume>:<page-range>1572&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/bjc.2017.313</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yiu</surname> <given-names>A</given-names>
</name>
<name>
<surname>van Hemelrijck</surname> <given-names>M</given-names>
</name>
<name>
<surname>Garmo</surname> <given-names>H</given-names>
</name>
<name>
<surname>Holmberg</surname> <given-names>L</given-names>
</name>
<name>
<surname>Malmstr&#xf6;m</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lambe</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study</article-title>. <source>Oncotarget</source>. (<year>2017</year>) <volume>8</volume>:<page-range>42332&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.18632/oncotarget.16198</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>W</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Siyin</surname> <given-names>ST</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>The relationship between serum uric acid and colorectal cancer: a prospective cohort study</article-title>. <source>Sci Rep</source>. (<year>2022</year>) <volume>12</volume>:<fpage>16677</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598&#x2013;022-20357&#x2013;7</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mi</surname> <given-names>N</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>Y</given-names>
</name>
<name>
<surname>He</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>High serum uric acid may associate with the increased risk of colorectal cancer in females: A prospective cohort study</article-title>. <source>Int J Cancer</source>. (<year>2022</year>) <volume>150</volume>:<page-range>263&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/ijc.33807</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname> <given-names>GD</given-names>
</name>
<name>
<surname>Ebrahim</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease</article-title>? <source>Int J Epidemiol</source>. (<year>2003</year>) <volume>32</volume>:<fpage>1</fpage>&#x2013;<lpage>22</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/ije/dyg070</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobylecki</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Afzal</surname> <given-names>S</given-names>
</name>
<name>
<surname>Nordestgaard</surname> <given-names>BG</given-names>
</name>
</person-group>. <article-title>Plasma urate, cancer incidence, and all-cause mortality: A mendelian randomization study</article-title>. <source>Clin Chem</source>. (<year>2017</year>) <volume>63</volume>:<page-range>1151&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1373/clinchem.2016.268185</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wong</surname> <given-names>MC</given-names>
</name>
</person-group>. <article-title>Association between serum uric acid and prostate cancer risk in East Asian populations: a Mendelian randomization study</article-title>. <source>Eur J Nutr</source>. (<year>2023</year>) <volume>62</volume>:<page-range>1323&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00394&#x2013;022-03076&#x2013;7</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horsfall</surname> <given-names>LJ</given-names>
</name>
<name>
<surname>Hall</surname> <given-names>IP</given-names>
</name>
<name>
<surname>Nazareth</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>Serum urate and lung cancer: a cohort study and Mendelian randomization using UK Biobank</article-title>. <source>Respir Res</source>. (<year>2021</year>) <volume>22</volume>:<fpage>179</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12931-021-01768-y</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Serum uric acid levels and risk of eight site-specific cancers: A mendelian randomization study</article-title>. <source>Front Genet</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>608311</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fgene.2021.608311</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>K&#xf6;ttgen</surname> <given-names>A</given-names>
</name>
<name>
<surname>Albrecht</surname> <given-names>E</given-names>
</name>
<name>
<surname>Teumer</surname> <given-names>A</given-names>
</name>
<name>
<surname>Vitart</surname> <given-names>V</given-names>
</name>
<name>
<surname>Krumsiek</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hundertmark</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Genome-wide association analyses identify 18 new loci associated with serum urate concentrations</article-title>. <source>Nat Genet</source>. (<year>2013</year>) <volume>45</volume>:<page-range>145&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ng.2500</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Battelli</surname> <given-names>MG</given-names>
</name>
<name>
<surname>Bortolotti</surname> <given-names>M</given-names>
</name>
<name>
<surname>Polito</surname> <given-names>L</given-names>
</name>
<name>
<surname>Bolognesi</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>The role of xanthine oxidoreductase and uric acid in metabolic syndrome</article-title>. <source>Biochim Biophys Acta Mol Basis Dis</source>. (<year>2018</year>) <volume>1864</volume>:<page-range>2557&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbadis.2018.05.003</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snezhkina</surname> <given-names>AV</given-names>
</name>
<name>
<surname>Kudryavtseva</surname> <given-names>AV</given-names>
</name>
<name>
<surname>Kardymon</surname> <given-names>OL</given-names>
</name>
<name>
<surname>Savvateeva</surname> <given-names>MV</given-names>
</name>
<name>
<surname>Melnikova</surname> <given-names>NV</given-names>
</name>
<name>
<surname>Krasnov</surname> <given-names>GS</given-names>
</name>
<etal/>
</person-group>. <article-title>ROS generation and antioxidant defense systems in normal and Malignant cells</article-title>. <source>Oxid Med Cell Longev</source>. (<year>2019</year>) <volume>2019</volume>:<elocation-id>6175804</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2019/6175804</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabbrini</surname> <given-names>E</given-names>
</name>
<name>
<surname>Serafini</surname> <given-names>M</given-names>
</name>
<name>
<surname>Colic Baric</surname> <given-names>I</given-names>
</name>
<name>
<surname>Hazen</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Klein</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects</article-title>. <source>Diabetes</source>. (<year>2014</year>) <volume>63</volume>:<page-range>976&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2337/db13&#x2013;1396</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cab&#x103;u</surname> <given-names>G</given-names>
</name>
<name>
<surname>Cri&#x219;an</surname> <given-names>TO</given-names>
</name>
<name>
<surname>Kl&#xfc;ck</surname> <given-names>V</given-names>
</name>
<name>
<surname>Popp</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Joosten</surname> <given-names>LA</given-names>
</name>
</person-group>. <article-title>Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia</article-title>. <source>Immunol Rev</source>. (<year>2020</year>) <volume>294</volume>:<fpage>92</fpage>&#x2013;<lpage>105</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/imr.12833</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x11f;uz</surname> <given-names>N</given-names>
</name>
<name>
<surname>K&#x131;r&#xe7;a</surname> <given-names>M</given-names>
</name>
<name>
<surname>&#xc7;etin</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ye&#x15f;ilkaya</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Effect of uric acid on inflammatory COX-2 and ROS pathways in vascular smooth muscle cells</article-title>. <source>J Recept Signal Transduct Res</source>. (<year>2017</year>) <volume>37</volume>:<page-range>500&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/10799893.2017.1360350</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>C-F</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>J-J</given-names>
</name>
<name>
<surname>Mi</surname> <given-names>N-N</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>Y-Y</given-names>
</name>
<name>
<surname>He</surname> <given-names>Q-S</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>Y-W</given-names>
</name>
<etal/>
</person-group>. <article-title>Associations between serum uric acid and hepatobiliary-pancreatic cancer: A cohort study</article-title>. <source>WJG</source>. (<year>2020</year>) <volume>26</volume>:<page-range>7061&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3748/wjg.v26.i44.7061</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname> <given-names>X-Y</given-names>
</name>
<name>
<surname>He</surname> <given-names>Q-S</given-names>
</name>
<name>
<surname>Jing</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yuan</surname> <given-names>J-Q</given-names>
</name>
</person-group>. <article-title>Serum uric acid levels and risk of kidney cancer incidence and mortality: A prospective cohort study</article-title>. <source>Cancer Med</source>. (<year>2020</year>) <volume>9</volume>:<page-range>5655&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cam4.3214</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>YR</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>SW</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>HY</given-names>
</name>
<name>
<surname>Shin</surname> <given-names>MH</given-names>
</name>
<etal/>
</person-group>. <article-title>Association between albumin, total bilirubin, and uric acid serum levels and the risk of cancer: A prospective study in a korean population</article-title>. <source>Yonsei Med J</source>. (<year>2021</year>) <volume>62</volume>:<page-range>792&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3349/ymj.2021.62.9.792</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname> <given-names>Y-J</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>YJ</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>E</given-names>
</name>
<name>
<surname>Park</surname> <given-names>B</given-names>
</name>
<name>
<surname>Kwon</surname> <given-names>J-W</given-names>
</name>
<name>
<surname>Heo</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Cancer risk in Korean patients with gout</article-title>. <source>Korean J Intern Med</source>. (<year>2022</year>) <volume>37</volume>:<page-range>460&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3904/kjim.2020.259</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>D</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Increased risk of cancer in relation to gout: A review of three prospective cohort studies with 50,358 subjects</article-title>. <source>Mediators Inflammation</source>. (<year>2015</year>) <volume>2015</volume>:<elocation-id>680853</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2015/680853</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ames</surname> <given-names>BN</given-names>
</name>
<name>
<surname>Cathcart</surname> <given-names>R</given-names>
</name>
<name>
<surname>Schwiers</surname> <given-names>E</given-names>
</name>
<name>
<surname>Hochstein</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis</article-title>. <source>Proc Natl Acad Sci U.S.A</source>. (<year>1981</year>) <volume>78</volume>:<page-range>6858&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.78.11.6858</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>X</given-names>
</name>
<name>
<surname>Su</surname> <given-names>C</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>B</given-names>
</name>
<name>
<surname>Du</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Uric acid enhances the antitumor immunity of dendritic cell-based vaccine</article-title>. <source>Sci Rep</source>. (<year>2015</year>) <volume>5</volume>:<elocation-id>16427</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/srep16427</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferreira</surname> <given-names>C</given-names>
</name>
<name>
<surname>Prestin</surname> <given-names>K</given-names>
</name>
<name>
<surname>Hussner</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zimmermann</surname> <given-names>U</given-names>
</name>
<name>
<surname>Meyer Zu Schwabedissen</surname> <given-names>HE</given-names>
</name>
</person-group>. <article-title>PDZ domain containing protein 1 (PDZK1), a modulator of membrane proteins, is regulated by the nuclear receptor THR&#x3b2;</article-title>. <source>Mol Cell Endocrinol</source>. (<year>2018</year>) <volume>461</volume>:<page-range>215&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mce.2017.09.017</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anzai</surname> <given-names>N</given-names>
</name>
<name>
<surname>Miyazaki</surname> <given-names>H</given-names>
</name>
<name>
<surname>Noshiro</surname> <given-names>R</given-names>
</name>
<name>
<surname>Khamdang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chairoungdua</surname> <given-names>A</given-names>
</name>
<name>
<surname>Shin</surname> <given-names>H-J</given-names>
</name>
<etal/>
</person-group>. <article-title>The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 <italic>via</italic> its C terminus</article-title>. <source>J Biol Chem</source>. (<year>2004</year>) <volume>279</volume>:<page-range>45942&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M406724200</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>D</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation</article-title>. <source>Oncogene</source>. (<year>2017</year>) <volume>36</volume>:<page-range>6119&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/onc.2017.199</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>C</given-names>
</name>
<name>
<surname>Tao</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Loss of PDZK1 expression activates PI3K/AKT signaling <italic>via</italic> PTEN phosphorylation in gastric cancer</article-title>. <source>Cancer Lett</source>. (<year>2019</year>) <volume>453</volume>:<page-range>107&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.canlet.2019.03.043</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>H</given-names>
</name>
<name>
<surname>Abd Elmageed</surname> <given-names>ZY</given-names>
</name>
<name>
<surname>Davis</surname> <given-names>C</given-names>
</name>
<name>
<surname>El-Bahrawy</surname> <given-names>AH</given-names>
</name>
<name>
<surname>Naura</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Ekaidi</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Correlation between PDZK1, Cdc37, Akt and breast cancer Malignancy: the role of PDZK1 in cell growth through Akt stabilization by increasing and interacting with Cdc37</article-title>. <source>Mol Med</source>. (<year>2014</year>) <volume>20</volume>:<page-range>270&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2119/molmed.2013.00166</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Maro</surname> <given-names>G</given-names>
</name>
<name>
<surname>Orlandella</surname> <given-names>FM</given-names>
</name>
<name>
<surname>Bencivenga</surname> <given-names>TC</given-names>
</name>
<name>
<surname>Salerno</surname> <given-names>P</given-names>
</name>
<name>
<surname>Ugolini</surname> <given-names>C</given-names>
</name>
<name>
<surname>Basolo</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of targets of Twist1 transcription factor in thyroid cancer cells</article-title>. <source>J Clin Endocrinol Metab</source>. (<year>2014</year>) <volume>99</volume>:<page-range>E1617&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1210/jc.2013&#x2013;3799</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Qian</surname> <given-names>C</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>HBV infection-related PDZK1 plays an oncogenic role by regulating the PI3K-akt pathway and fatty acid metabolism and enhances immunosuppression</article-title>. <source>J Immunol Res</source>. (<year>2022</year>) <volume>2022</volume>:<elocation-id>8785567</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2022/8785567</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allegrini</surname> <given-names>S</given-names>
</name>
<name>
<surname>Garcia-Gil</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pesi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Camici</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tozzi</surname> <given-names>MG</given-names>
</name>
</person-group>. <article-title>The Good, the Bad and the New about Uric Acid in Cancer</article-title>. <source>Cancers (Basel)</source>. (<year>2022</year>) <volume>14</volume>:<fpage>4959</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cancers14194959</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>